A multicenter, open-label, phase 1b clinical trial (NCT02715531) evaluated the effectiveness of atezolizumab (anti-PD-L1 agent) combined with bevacizumab (anti-VEGF agent) in the treatment of HCC (54). This evidence concerns the gene VEGFA and hepatocellular carcinoma.